Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells $154,539.24 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 3,084 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $154,539.24. Following the completion of the sale, the general counsel now directly owns 51,712 shares in the company, valued at approximately $2,591,288.32. The trade was a 5.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Bryan Wahl also recently made the following trade(s):

• On Tuesday, March 18th, Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $46.29, for a total value of $154,654.89.

Tarsus Pharmaceuticals Trading Up 0.1 %

TARS stock opened at $49.97 on Friday. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -13.12 and a beta of 1.05. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The business has a fifty day simple moving average of $48.48 and a 200-day simple moving average of $45.35. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. On average, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Institutional Trading of Tarsus Pharmaceuticals

Several large investors have recently added to or reduced their stakes in TARS. Mutual of America Capital Management LLC acquired a new stake in Tarsus Pharmaceuticals in the 3rd quarter valued at $4,291,000. Jennison Associates LLC increased its holdings in Tarsus Pharmaceuticals by 47.2% in the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after purchasing an additional 698,712 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Tarsus Pharmaceuticals in the 3rd quarter valued at $282,000. Charles Schwab Investment Management Inc. increased its holdings in Tarsus Pharmaceuticals by 10.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 290,009 shares of the company’s stock valued at $9,538,000 after purchasing an additional 28,130 shares in the last quarter. Finally, FMR LLC increased its holdings in Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after purchasing an additional 3,537 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on TARS shares. Oppenheimer increased their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Guggenheim reissued a “buy” rating and set a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Jefferies Financial Group increased their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. HC Wainwright reissued a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Barclays reduced their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.